Precision treatment based on gene-type type is the future development direction of giST treatment of gastrointestinal mesomas.

!----.In today's precision treatment of tumors, as the first to carry out genetic ally formations of solid tumors, gastrointestinal mesomas (GIST) also became one of the topics of the conference., what is the current and future prospects of GIST precision treatment by genotype? Special invitation to The Sixth Hospital of Zhongshan University, Professor Deng Yanhong, on the above-mentioned issues to interview Deng Yanhong, director physician, doctoral tutor, Sun Yat-sen University affiliated Sixth Hospital Oncology Director, China Colorectal Cancer Standard (National Health Care Planning Commission) expert group member, Vice President of the Chinese Geriatric Synody Medical Association Branch, China Anti-Cancer Association, Colorectal Cancer Professional Committee Youth Committee, China Vice Chairman of the Youth Committee of the Colorectal Oncology Branch of the Physicians Association, the Chairman of the Professional Committee of Digestive Oncology of Guangdong Provincial Association of Women Physicians, the Chairman of the Youth Committee of the Southern Cancer Clinical Research Association (CSWOG) and the Vice Chairman of the Professional Committee for Colorectal Cancer, the Standing Committee of the Integrated Oncology Branch of the China Anti-Cancer Association, the Standing Committee of the Professional Committee of the Chinese Association of Cancer And Cancer, and the Standing Committee of the Youth Committee of the China Clinical Oncology Association.GIST targeted treatment status GIST is a solid tumor from the source of gastrointestinal inter-intestinal lobe tissue, with surgery and drug therapy as the main treatment strategy.despite the low incidence of the disease, this year's POST-ASCO meeting added GIST because GIST is the first malignant tumor to undergo genotype distype therapy and has made rapid progress in the field of precision tumor therapy.the earliest targeted treatment drug for GIST is imatinib, which in 1999 opened the era of targeted treatment in the field of tumors, GIST is one of the first to start precision treatment of the tumor, the disease targeted treatment is very worthy of research.in the past, GIST mainly in the first line of imatini treatment, however, with the molecular mechanism level of research, found that GIST in the target of diversity, its driving gene mutations not only including KIT exon 11, 9, 13 and 17 mutations, but also PDGFRA mutation, which also contains four exon mutations.different exosome mutations are different in sensitivity to the drug, for example: imatinib is slightly less effective in patients with KIT exoon 9 mutation, while shonetinib is slightly less effective, i.e. patients with the exosome 9 mutation are more sensitive to shonetinib;although THE diagnosis and treatment of GIST is progressing rapidly, but the drug research and development for the disease is relatively slow, because of the superior efficacy of Imatinib, therefore, GIST drug research and development needs, less than lung cancer urgent, therefore, since 1999, GIST approved in china only first-line imatini, second-line shoneni and third-line rigofini these three drugs, when these three drugs appear drug resistance, this is less important to choose from.relapsed transfer of GIST multi-line drug resistance treatment strategy is well known, GIST is the development of relatively slow tumor, many patients in the third-line treatment, the general condition is still good.against patients with relatively good PS scores, after the presence of drug resistance in Imatinib, it is possible to use imatinib again or to target drugs targeted at other targets.GIST may have both sensitivity and drug resistance mutations, so a combination of treatments can be taken in the future.for example, for patients with exosome 11 and exon 17 mutations, for example, imartinib and rigofenib may be considered for combination therapy, which may also be combined with other small moleculeSTKI.may in May this year, ripretinib has been approved in the United States as a standard four-line treatment for patients with recurrent metastasis GIST.the drug has also been in the domestic bridging test, it is estimated that soon will also be approved in China, China's recurrent transfer GIST patients four-line standard treatment drugs.Gene-based treatment is the future development direction of GIST therapy In view of the development of tumors based on molecular dystotype therapy, the future selection of drugs based on genotype will be one of its future development directions.at the same time, it is possible to break the limit on the number of lines in the future, from the first line will be treated according to the genotype. at this year's ASCO conference, it can be seen that joining the combination of treatments, with enough imatinib efficacy, can still benefit some patients more. in small samplestudies, patients without progression can be extended from 20 months to 30 months. in short, in the future, combination therapy may replace single-drug therapy, whether first-line or second-line combination therapy, will be treated with genotype, which is the general trend of the future. Linda Source: Tumor Information !-- End of Content Presentation -- !-- Determine Signed-up End-